Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1
zadetkov: 3
1.
  • Association between the cer... Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study
    Nené, Nuno R, PhD; Reisel, Daniel, PhD; Leimbach, Andreas, PhD ... The lancet oncology, 08/2019, Letnik: 20, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    SummaryBackgroundVarious factors—including age, family history, inflammation, reproductive factors, and tubal ligation—modulate the risk of ovarian cancer. In this study, our aim was to establish ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK, ZRSKP

PDF
2.
  • Standard first-line chemoth... Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial
    du Bois, Andreas, Prof; Kristensen, Gunnar, Prof; Ray-Coquard, Isabelle, Prof ... The lancet oncology, 2016, January 2016, 2016-Jan, 2016-01-00, 20160101, 2016-01, Letnik: 17, Številka: 1
    Journal Article, Web Resource
    Recenzirano
    Odprti dostop

    Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor, platelet-derived growth factor receptor, and ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK, ZRSKP
3.
  • Niraparib plus bevacizumab ... Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial
    Mirza, Mansoor Raza, MD; Åvall Lundqvist, Elisabeth, PhD; Birrer, Michael J, Prof ... The lancet oncology, 10/2019, Letnik: 20, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    SummaryBackgroundPlatinum-based chemotherapy is the foundation of treatment for platinum-sensitive recurrent ovarian cancer, but has substantial toxicity. Bevacizumab and maintenance poly(ADP-ribose) ...
Celotno besedilo
Dostopno za: GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK, ZRSKP

Nalaganje filtrov